First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across 10 sites in India
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The company has to approach the DCGI for approval to commence the trials
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
Subscribe To Our Newsletter & Stay Updated
